Royal Bank of Canada’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20K | Buy |
4,319
+3,469
| +408% | +$21.2K | ﹤0.01% | 5890 |
|
|
2025
Q4 | $15K | Sell |
850
-359
| -30% | -$5.36K | ﹤0.01% | 6189 |
|
|
2025
Q3 | $17K | Sell |
1,209
-241
| -17% | -$2.77K | ﹤0.01% | 6268 |
|
|
2025
Q2 | $12K | Buy |
1,450
+600
| +71% | +$4.38K | ﹤0.01% | 6425 |
|
|
2025
Q1 | $5K | Buy |
850
+767
| +924% | +$6.7K | ﹤0.01% | 6339 |
|
|
2024
Q4 | $1K | Buy |
83
+66
| +388% | +$695 | ﹤0.01% | 6754 |
|
|
2024
Q3 | $0 | Sell |
17
-2,028
| -99% | -$17.4K | ﹤0.01% | 6832 |
|
|
2024
Q2 | $17K | Sell |
2,045
-9,460
| -82% | -$142K | ﹤0.01% | 6125 |
|
|
2024
Q1 | $200K | Buy |
11,505
+10,285
| +843% | +$183K | ﹤0.01% | 4689 |
|
|
2023
Q4 | $16K | Sell |
1,220
-1,182
| -49% | -$27.6K | ﹤0.01% | 6370 |
|
|
2023
Q3 | $88K | Buy |
2,402
+334
| +16% | +$14.9K | ﹤0.01% | 5459 |
|
|
2023
Q2 | $83K | Buy |
2,068
+242
| +13% | +$13.7K | ﹤0.01% | 5467 |
|
|
2023
Q1 | $132K | Buy |
1,826
+802
| +78% | +$77.8K | ﹤0.01% | 4950 |
|
|
2022
Q4 | $84K | Buy |
1,024
+252
| +33% | +$26.3K | ﹤0.01% | 5583 |
|
|
2022
Q3 | $73K | Sell |
772
-13
| -2% | -$1.46K | ﹤0.01% | 5511 |
|
|
2022
Q2 | $152K | Sell |
785
-253
| -24% | -$41.3K | ﹤0.01% | 5022 |
|
|
2022
Q1 | $241K | Buy |
1,038
+80
| +8% | +$25.5K | ﹤0.01% | 4918 |
|
|
2021
Q4 | $377K | Buy |
958
+417
| +77% | +$176K | ﹤0.01% | 4726 |
|
|
2021
Q3 | $242K | Sell |
541
-4
| -0.7% | -$1.43K | ﹤0.01% | 5005 |
|
|
2021
Q2 | $212K | Sell |
545
-267
| -33% | -$95.2K | ﹤0.01% | 5026 |
|
|
2021
Q1 | $292K | Buy |
812
+185
| +30% | +$81.8K | ﹤0.01% | 4636 |
|
|
2020
Q4 | $308K | Buy |
627
+7
| +1% | +$3.23K | ﹤0.01% | 4524 |
|
|
2020
Q3 | $201K | Sell |
620
-49
| -7% | -$16.7K | ﹤0.01% | 4549 |
|
|
2020
Q2 | $243K | Buy |
669
+651
| +3,617% | +$164K | ﹤0.01% | 4308 |
|
|
2020
Q1 | $4K | Sell |
18
-120
| -87% | -$38.1K | ﹤0.01% | 6095 |
|
|
2019
Q4 | $57K | Sell |
138
-117
| -46% | -$40.3K | ﹤0.01% | 5389 |
|
|
2019
Q3 | $90K | Buy |
255
+20
| +9% | +$7.46K | ﹤0.01% | 4849 |
|
|
2019
Q2 | $118K | Buy |
235
+2
| +0.9% | +$1.41K | ﹤0.01% | 4780 |
|
|
2019
Q1 | $231K | Buy |
233
+6
| +3% | +$5.58K | ﹤0.01% | 4261 |
|
|
2018
Q4 | $197K | Sell |
227
-51
| -18% | -$47.4K | ﹤0.01% | 4357 |
|
|
2018
Q3 | $288K | Buy |
278
+37
| +15% | +$36.2K | ﹤0.01% | 4266 |
|
|
2018
Q2 | $222K | Buy |
241
+229
| +1,908% | +$246K | ﹤0.01% | 4348 |
|
|
2018
Q1 | $12K | Buy |
12
+7
| +140% | +$6.38K | ﹤0.01% | 5643 |
|
|
2017
Q4 | $2K | Sell |
5
-86
| -95% | -$31.8K | ﹤0.01% | 6255 |
|
|
2017
Q3 | $37K | Buy |
91
+74
| +435% | +$27.9K | ﹤0.01% | 5587 |
|
|
2017
Q2 | $5K | Sell |
17
-28
| -62% | -$10.8K | ﹤0.01% | 6029 |
|
|
2017
Q1 | $22K | Sell |
45
-4
| -8% | -$1.66K | ﹤0.01% | 5565 |
|
|
2016
Q4 | $17K | Buy |
49
+20
| +69% | +$8.47K | ﹤0.01% | 5848 |
|
|
2016
Q3 | $15K | Sell |
29
-2
| -6% | -$1.09K | ﹤0.01% | 5641 |
|
|
2016
Q2 | $18K | Hold |
31
| – | – | ﹤0.01% | 5547 |
|
|
2016
Q1 | $14K | Buy |
31
+27
| +675% | +$12.2K | ﹤0.01% | 5613 |
|
|
2015
Q4 | $2K | Sell |
4
-29
| -88% | -$21.9K | ﹤0.01% | 6348 |
|
|
2015
Q3 | $25K | Sell |
33
-14
| -30% | -$17.1K | ﹤0.01% | 5471 |
|
|
2015
Q2 | $63K | Buy |
+47
| New | +$53.9K | ﹤0.01% | 5097 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6116 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6154 |
|
Other funds holding ATRA
RG
VCM
EC
Royal Bank of Canada's ATRA Position: Q1 2026 in Review
Royal Bank of Canada increased its Atara Biotherapeutics (ATRA) stake by 408% in Q1 2026, buying an estimated $21.2K and bringing the position to 4,319 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #5890.
Royal Bank of Canada first reported a position in ATRA in Q2 2015 and has held it in 44 quarters since. The position peaked at $377K in Q4 2021. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.
- Royal Bank of Canada held 4,319 shares of Atara Biotherapeutics worth $20K as of Q1 2026.
- Royal Bank of Canada bought 3,469 Atara Biotherapeutics shares in Q1 2026, an estimated $21.2K.
- Atara Biotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5890 holding.
- Royal Bank of Canada first reported a position in Atara Biotherapeutics in Q2 2015 and has held it in 44 quarters since.
- Royal Bank of Canada's Atara Biotherapeutics position peaked at $377K in Q4 2021.
- 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.